SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
508 36 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
477Enrolment rate and centers opening rate for melanoma P3 still *confuse* all whatMiljenko Zuanic-6/4/2019
476Shares are up nearly $3.00 per share in pre-market, so Wall Street must like thArthur Radley-6/3/2019
475214 at ASCO-2019 nektar.comMiljenko Zuanic-6/1/2019
474Regorafenib for osteosarcoma: ascopubs.orgMiljenko Zuanic-5/30/2019
473That was my point/concern. And Mary mentioned on cc, only FEW more subjects to Miljenko Zuanic-5/16/2019
472Unless the sarcoma-IST data to be presented at ASCO are much, much better than tDewDiligence_on_SI-5/16/2019
471So much about accelerated approval,......... why they even mentioned at cc????Miljenko Zuanic-5/16/2019
470That trial, two centers (second is Anderson), was on my screen from day one. IncMiljenko Zuanic-5/9/2019
469They certainly devoted a lot of time to the sarcoma IST conducted by Dr. D'ADewDiligence_on_SI-5/9/2019
468Very informative 1Q cc: finance.yahoo.comMiljenko Zuanic-5/9/2019
467twitter.comMiljenko Zuanic-3/2/2019
466Cetus was swallowed by Chiron (which develop Proleukin), which was bought by NovMiljenko Zuanic-2/26/2019
465Whatever happened to Cetus and Chiron IL-2? Are they still relevant?semi_infinite -2/26/2019
464Competitor: fiercebiotech.comMiljenko Zuanic-2/26/2019
463Yes, it looks that way. Time-passed is too short to have many new updates (numbeMiljenko Zuanic-2/26/2019
462I don't know why they are having a call if its not substantially more of an ghmm-2/26/2019
461How long will they talk now, slicing 10 subjects from P1-escalation phase (this Miljenko Zuanic-2/25/2019
460<BMY and NKTR agree, evidently.> With not so strong conviction...only sinMiljenko Zuanic-2/11/2019
459BMY and NKTR agree, evidently.DewDiligence_on_SI-2/11/2019
458ASCO-GU meetinglibrary.asco.org <22 pts had available baseline PD-L1 resultsMiljenko Zuanic-2/11/2019
457Than again, he is/was strong seller from 2014! finviz.comMiljenko Zuanic-1/30/2019
456Nicholson J. sold without any *reserve* for taxes. Well, he can sell from main hMiljenko Zuanic-1/30/2019
455Oppenheimer join club with 10% stake: secfilings.nasdaq.comMiljenko Zuanic-1/19/2019
454Neoleukin...... endpts.comscaram(o)uche-1/11/2019
453Given that pointer came from Andy Biotech, imagine most have seen this..... natscaram(o)uche-1/10/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):